Form 4: BioXcel CSO Granted 9,000 Restricted Stock Units

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, was granted 9,000 Restricted Stock Units (RSUs) on August 1, 2025, which will vest nine months from the grant date.

Summary

• Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, Inc. (BTAI), was granted 9,000 Restricted Stock Units (RSUs).
• The grant date for these RSUs was August 1, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest 100% on or within thirty (30) days of nine months from the grant date, contingent on continued employment with the Issuer or a subsidiary.

Sentiment

Score: 6

Explanation: The grant of RSUs to a key executive is a positive for retention and alignment of interests, but it's a routine compensation event and not indicative of significant operational or financial news.

Positives

• Grant of 9,000 Restricted Stock Units to the Chief Scientific Officer aligns management incentives with shareholder value.
• The vesting schedule encourages long-term retention of key personnel.

Negatives

• Potential for minor future dilution upon RSU vesting and conversion to common stock.

Risks

• Vesting of RSUs is subject to the reporting person's continued employment with the Issuer or a subsidiary.

Future Outlook

The 9,000 Restricted Stock Units granted to the Chief Scientific Officer are scheduled to vest on or within thirty days of nine months from the August 1, 2025 grant date, contingent on continued employment.

Industry Context

This is a routine executive compensation event common across the biotechnology and pharmaceutical industries to attract and retain talent, aligning executive interests with long-term company performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) is a standard form of equity compensation in the biotechnology sector, comparable to practices at companies like Moderna, Pfizer, or Amgen, which frequently use RSUs to incentivize executives.
• The vesting schedule of approximately nine months is relatively short for a full grant, though often RSUs vest over multiple years. This specific vesting could be tied to a specific performance milestone or a retention bonus.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon RSU conversion, but also improved executive retention and alignment.
• Employees: Positive for the Chief Scientific Officer receiving the grant, indicating continued compensation and incentive.

Next Steps

• Vesting of 9,000 Restricted Stock Units on or within thirty days of nine months from August 1, 2025, subject to continued employment.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, SEC Form 4, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Frank Yocca, Chief Scientific Officer